Cannabis is like wine: the Chilean perspective

Total
2
Shares

An interview with: Nicolás DormalC

Fundación Daya was the first organization to receive a permit to grow cannabis in Latin America and was the first to begin cultivation in Chile. Daya has been treating patients with medicinal marijuana for four years and in January entered into partnership with Khiron Life Sciences to develop clinical trials in Chile. 

CCI: What cannabis-based treatment options are open to Chilean patients? 

ND: After a medical appointment to determine if they are eligible, we provide patients with two options. The first is to cultivate their own plants at home, which is allowed by Chilean law. We teach them how to grow as well as some basic recipes for extraction. The second option is to get a prescription. Knop Laboratorios are distributing Cannabiol in 15 cities in Chile through their associated pharmacies. Cannabiol is the first cannabis-based medicine in Latin America, and sells at a value 12 times cheaper than Sativex. However, it is the only licensed formulation, and it does not cover the number of pathologies we treat. Take refractory epilepsy, the treatment mostly requires higher CBD formulations, even with some THC presence. These formulations still don’t exist in the market, and self-cultivation is replacing this need. 

We also believe that thanks to our climate – and given the right regulations – Chile has the potential to be a producer.

CCI: Why have the Uruguayan and Colombian cannabis markets taken off while Chile has remained slow? 

ND: We were the first to start medicinal cannabis development and now are the last. There is a lack of vision from the authorities in creating a set of clear rules that attract foreign or local investment. Aside from Decrees 404 and 405, which allow for imports, exports and prescription, there is no specific regulation for cannabis. We don’t even have licenses: companies have to ask for permits each year, and this is not attractive for investors. Nevertheless, there has been an interest due to our progress for local and international companies starting their activities. Sooner or later regulators will need to update their procedures. 

CCI: Even so, major Canadian firms are entering the market via distribution agreements… 

ND: Yes, they are coming to the market with their brands and will begin clinical trials to register products in Chile. However, we also believe that thanks to our climate – and given the right regulations – Chile has the potential to be a producer. We have Mediterranean and mountain climates with summers of up to eight months without rain, many hours of light, and clear water sources coming from the mountains. We can cultivate huge plants that produce three kilos of dry flower each. The production on one hectare can be up to 1.5 tons of dry flower. This is equivalent to indoor cultivation in three harvests, so one harvest produces the same as of three in Colombia, with lower costs than indoor and greenhouse cultivation. 

CCI: What is the long term potential of Chilean cannabis? 

ND: In my opinion, Chilean cannabis is a bit like its wine: very high quality, at low costs. We have high microbiological safety, with very high-performing plants. Also, Chile has a very high level of phytosanitary control. The key is to cultivate in September and harvest in March. 

CCI: Are Chileans open to medicinal cannabis? 

ND: Yes, 86% of Chileans support medicinal cannabis, the highest level in the region. Daya has worked with 25,000 patients, all of them using medicinal cannabis and most of them cultivating in their homes using our protocols. Historically, Chile was also a hemp producer – in the 1940s it was the third largest in the world. We have a huge culture of decriminalization, the Chilean society is not conservative, but the political elite is. They are the ones who need to change their perspective because this is an industry like any other. 

Subscribe to our readers list and receive our free month edition

You May Also Like

More than the sun shining in Colombia

An interview with: Alfredo Pascual Alfredo is a Germany- based International Analyst for Marijuana Business Daily, specializing in international cannabis markets and regulations. Previously, he did business development for ICC…
View Post

Doctor’s Orders

Tittle: Doctor’s orders An interview with: Paola Cubillos, M.D., N.D. Paola Cubillos is an experienced physician and medicinal cannabis advocate. Colombian by birth, she studied and worked in Toronto for…
View Post

Early applicant

Formerly a talent manager for renowned Colombian musicians, Mauricio Krausz discovered the benefits of medical cannabis at Barcelona’s “Cannabis Clubs”. When the Colombian government legalized medicinal cannabis in 2015, Mauricio’s…
View Post

Alvaro Torres

CEO Khiron Lifesciences Corp. In May, Khiron Life Sciences became the first First Canadian Cannabis Company with Core Operations in Colombia to List on Any Exchange Globally with their listing…
View Post

Angelo Investor

Known as the father of the cannabis industry, Steve DeAngelo is an entrepreneur, activist, author and on-screen personality. He co- founded several iconic cannabis businesses, including Harborside, one of the…
View Post